showed that recombinant human VEGF165b inhibits experimental murine choroidal neovascularization, but did not show an effect of bevacizumab on mouse models of choroidal neovascularization. We do note that bevacizumab has an effect on reducing corneal neovascularization in the mouse eye. 3, 4 It appears that the route and timing of administration play a role in this effect. In our model, intracameral bevacizumab reduced the number of hepatic micrometastases from ocular melanoma. We cannot exclude that this may have been due to selective inhibition of intraocular melanoma cells rather than an antiangiogenic effect.
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